{"id":43613,"date":"2015-09-17T11:25:58","date_gmt":"2015-09-17T16:25:58","guid":{"rendered":"https:\/\/content.findlaw-admin.com\/ability-legal\/contracts\/uncategorized\/share-purchase-agreement-rosemont-pharmaceuticals-ltd-ned-int.html"},"modified":"2015-09-17T11:25:58","modified_gmt":"2015-09-17T16:25:58","slug":"share-purchase-agreement-rosemont-pharmaceuticals-ltd-ned-int","status":"publish","type":"corporate_contracts","link":"https:\/\/corporate.findlaw.com\/contracts\/planning\/share-purchase-agreement-rosemont-pharmaceuticals-ltd-ned-int.html","title":{"rendered":"Share Purchase Agreement – Rosemont Pharmaceuticals Ltd., NED-INT Holdings Ltd., Akzo Nobel NV and Bio-Technology General Corp."},"content":{"rendered":"
Dated \n20 September 2002 <\/font><\/p>\n\n
SHARE PURCHASE AGREEMENT  <\/b><\/font><\/p>\n\n
relating to <\/font><\/p>\n\n
ROSEMONT PHARMACEUTICALS LIMITED  <\/b><\/font><\/p>\n\n
between <\/font><\/p>\n\n
NED-INT HOLDINGS LTD  <\/b><\/font><\/p>\n\n
and <\/font><\/p>\n\n
AKZO NOBEL N.V.  <\/b><\/font><\/p>\n\n
on the one side <\/font><\/p>\n\n
BIO-TECHNOLOGY GENERAL CORP.  <\/b><\/font><\/p>\n\n
on the other side <\/font><\/p>\n\n
\n\n\n\n\n
 \n \n
<\/a><\/font>CONTENTS    
  <\/b><\/font><\/p>\n\n\n<\/pre>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
CLAUSE
 <\/b><\/font><\/th>\n		 <\/font><\/th>\nPage<\/b><\/font><\/p>\n
<\/th>\n<\/tr>\n
  1. DEFINITIONS AND INTERPRETATION<\/font><\/td>\n <\/font><\/td>\n1<\/font><\/td>\n<\/tr>\n
  2. SALE AND PURCHASE<\/font><\/td>\n <\/font><\/td>\n5<\/font><\/td>\n<\/tr>\n
  3. CONSIDERATION<\/font><\/td>\n <\/font><\/td>\n6<\/font><\/td>\n<\/tr>\n
  4. COMPLETION<\/font><\/td>\n <\/font><\/td>\n6<\/font><\/td>\n<\/tr>\n
  5. WARRANTIES<\/font><\/td>\n <\/font><\/td>\n10<\/font><\/td>\n<\/tr>\n
  6. SPECIFIC INDEMNIFICATIONS<\/font><\/td>\n <\/font><\/td>\n10<\/font><\/td>\n<\/tr>\n
  7. LIMITATION OF VENDOR’S LIABILITY<\/font><\/td>\n <\/font><\/td>\n10<\/font><\/td>\n<\/tr>\n
  8. PROTECTION OF GOODWILL AND TRADE SECRETS<\/font><\/td>\n <\/font><\/td>\n11<\/font><\/td>\n<\/tr>\n
  9. OBLIGATIONS OF THE PURCHASER<\/font><\/td>\n <\/font><\/td>\n12<\/font><\/td>\n<\/tr>\n
10. PENSIONS AND EMPLOYMENT<\/font><\/td>\n <\/font><\/td>\n14<\/font><\/td>\n<\/tr>\n
11. DEBT AND GUARANTEES<\/font><\/td>\n <\/font><\/td>\n14<\/font><\/td>\n<\/tr>\n
12. LAND CERTIFICATE<\/font><\/td>\n <\/font><\/td>\n16<\/font><\/td>\n<\/tr>\n
13. ANNOUNCEMENTS<\/font><\/td>\n <\/font><\/td>\n16<\/font><\/td>\n<\/tr>\n
14. FURTHER ASSURANCE<\/font><\/td>\n <\/font><\/td>\n16<\/font><\/td>\n<\/tr>\n
15. ASSIGNMENT<\/font><\/td>\n <\/font><\/td>\n16<\/font><\/td>\n<\/tr>\n
16. ENTIRE AGREEMENT: REMEDIES<\/font><\/td>\n <\/font><\/td>\n17<\/font><\/td>\n<\/tr>\n
17. WAIVER AND VARIATION<\/font><\/td>\n <\/font><\/td>\n17<\/font><\/td>\n<\/tr>\n
18. COSTS AND EXPENSES<\/font><\/td>\n <\/font><\/td>\n18<\/font><\/td>\n<\/tr>\n
19. NOTICES<\/font><\/td>\n <\/font><\/td>\n18<\/font><\/td>\n<\/tr>\n
20. COUNTERPARTS<\/font><\/td>\n <\/font><\/td>\n19<\/font><\/td>\n<\/tr>\n
21. INVALIDITY<\/font><\/td>\n <\/font><\/td>\n19<\/font><\/td>\n<\/tr>\n
22. AGREEMENT TO CONTINUE IN FULL FORCE AND EFFECT<\/font><\/td>\n <\/font><\/td>\n19<\/font><\/td>\n<\/tr>\n
23. THIRD PARTY RIGHTS<\/font><\/td>\n <\/font><\/td>\n19<\/font><\/td>\n<\/tr>\n
24. GOVERNING LAW AND JURISDICTION<\/font><\/td>\n <\/font><\/td>\n19<\/font><\/td>\n<\/tr>\n<\/table>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\nSchedules<\/font><\/td>\n
 <\/font><\/td>\n
\n <\/font><\/td>\n<\/tr>\n
Schedule 1: Properties<\/font><\/td>\n <\/font><\/td>\n <\/font><\/td>\n<\/tr>\n
Schedule 2: The Company<\/font><\/td>\n <\/font><\/td>\n <\/font><\/td>\n<\/tr>\n
Schedule 3: The Warranties<\/font><\/td>\n <\/font><\/td>\n <\/font><\/td>\n<\/tr>\n
Schedule 4: Pensions<\/font><\/td>\n <\/font><\/td>\n <\/font><\/td>\n<\/tr>\n
Schedule 5: Actuaries Letter<\/font><\/td>\n <\/font><\/td>\n <\/font><\/td>\n<\/tr>\n
Schedule 6: Completion<\/font><\/td>\n <\/font><\/td>\n <\/font><\/td>\n<\/tr>\n
Schedule 7: Limitations on Liability<\/font><\/td>\n <\/font><\/td>\n <\/font><\/td>\n<\/tr>\n
Schedule 8: Intellectual Property<\/font><\/td>\n <\/font><\/td>\n <\/font><\/td>\n<\/tr>\n
Schedule 9: Transitional Arrangements<\/font><\/td>\n <\/font><\/td>\n <\/font><\/td>\n<\/tr>\n

\nEXHIBITS<\/font><\/td>\n
 <\/font><\/td>\n
\n <\/font><\/td>\n<\/tr>\n
Exhibit 1: Information Memorandum<\/font><\/td>\n <\/font><\/td>\n <\/font><\/td>\n<\/tr>\n
Exhibit 2: KPMG Report<\/font><\/td>\n <\/font><\/td>\n <\/font><\/td>\n<\/tr>\n
Exhibit 3: Tax Deed<\/font><\/td>\n <\/font><\/td>\n <\/font><\/td>\n<\/tr>\n
Exhibit 4: MIAC 9C-5a<\/font><\/td>\n <\/font><\/td>\n <\/font><\/td>\n<\/tr>\n<\/table>\n
\n
THIS AGREEMENT<\/b><\/font> is dated this 20th<\/sup> day of September 2002 <\/font><\/p>\n
PARTIES  <\/b><\/font><\/p>\n
\n
(1)<\/font><\/dt>\n
NED-INT HOLDINGS LTD<\/b><\/font> of Oriel House, 16 Connaught Place, London W2 2ZB, England(the <\/font> Vendor<\/b><\/font>); and <\/p>\n
<\/font><\/dd>\n
(2)<\/font><\/dt>\n
AKZO NOBEL N.V.<\/b><\/font>, Velperweg, 6824 BM Arnhem, The Netherlands (the <\/font>Guarantor<\/b><\/font>); and <\/p>\n
<\/font><\/dd>\n
(3)<\/font><\/dt>\n
BIO-TECHNOLOGY GENERAL CORP.<\/b><\/font> whose registered office is at 70 Wood Avenue South, Iselin, New Jersey 08830, USA or such
\nother of its Affiliates from time to time as it may nominate pursuant to Clause 9.6 (the <\/font>Purchaser<\/b><\/font>). <\/font><\/dd>\n<\/dl>\n
BACKGROUND  <\/b><\/font><\/p>\n
\n
(A)<\/font><\/dt>\n
The
\nVendor is the legal and beneficial owner of the entire issued share capital of Rosemont Pharmaceuticals Limited (the <\/font>Company<\/b><\/font>),
\nfurther details of which are set out in Schedule 2. <\/p>\n
<\/font><\/dd>\n
(B)<\/font><\/dt>\n
The
\nVendor has agreed to sell the Shares to the Purchaser and the Purchaser has agreed to purchase the Shares for the Purchase Price and upon and subject to the terms and conditions
\nof this Agreement. <\/font><\/dd>\n<\/dl>\n
IT IS AGREED AS FOLLOWS:  <\/b><\/font><\/p>\n
\n
1.<\/b><\/font><\/dt>\n
DEFINITIONS AND INTERPRETATION<\/b><\/font> <\/p>\n
<\/font><\/dd>\n
1.1<\/font><\/dt>\n
In
\nthis Agreement the following words and expressions have the meanings set opposite them: <\/font><\/dd>\n<\/dl>\n